(C) Reuters. FILE PHOTO: Syringes filled with a dose of the Moderna COVID-19 vaccine sit on a table during an employee vaccination at the Sarasota Memorial Hospital in Sarasota, Florida, U.S., September 24, 2021. REUTERS/Shannon Stapleton
(Reuters) – Moderna (NASDAQ:MRNA) Inc on Tuesday said the U.S. Food and Drug Administration should authorize booster doses of its COVID-19 vaccine in fully vaccinated older adults and other high-risk individuals.
The company said its data supports the public health benefit of a booster dose of its vaccine to restore immune response, while reducing the number of “breakthrough” infections in fully-vaccinated adults.
Moderna’s comments were released in briefing documents ahead of a Thursday meeting of the FDA’s outside expert advisers to discuss the booster dose.
Moderna seeks COVID-19 vaccine booster clearance in older adults, high-risk individuals
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.